Search research articles
Contact Us
Filters
Showing results (31-40 of 76) with videos related to
Page
of 8
Sort By:
Human Gene Therapy. Clinical Development
|
October 9, 2013
Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer
May C I van Schalkwyk, Sophie E Papa, Jean-Pierre Jeannon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
Effect of patient socioeconomic status on access to early-phase cancer trials
Aisyah Mohd Noor, Debashis Sarker, Suzanne Vizor, et al.
Investigational New Drugs
|
January 1, 1990
Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504)
R L Stephens, P Goodman, E D Crawford, et al.
Cancer Immunology, Immunotherapy : CII
|
July 31, 2016
Beta-glucan contamination of pharmaceutical products: How much should we accept?
Claire Barton, Kim Vigor, Robert Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma
Sarah M Rudman, Michael B Jameson, Mark J McKeage, et al.
Biotechnology Progress
|
September 8, 2016
Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies
Kim Vigor, John Emerson, Robert Scott, et al.
Mabs
|
February 5, 2014
Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency
Louise Saul, Debra H Josephs, Keith Cutler, et al.
The Journal of Biological Chemistry
|
June 22, 2010
Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4
Scott Wilkie, Sophie E Burbridge, Laura Chiapero-Stanke, et al.
Antibodies (Basel, Switzerland)
|
October 21, 2020
IgE Antibodies against Cancer: Efficacy and Safety
Jitesh Chauhan, Alex J McCraw, Mano Nakamura, et al.
Molecular Cancer Therapeutics
|
November 12, 2014
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma
Kristina M Ilieva, Isabel Correa, Debra H Josephs, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 76) with videos related to
Sort By:
Page
of 8
Human Gene Therapy. Clinical Development
|
October 9, 2013
Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer
May C I van Schalkwyk, Sophie E Papa, Jean-Pierre Jeannon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
Effect of patient socioeconomic status on access to early-phase cancer trials
Aisyah Mohd Noor, Debashis Sarker, Suzanne Vizor, et al.
Investigational New Drugs
|
January 1, 1990
Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504)
R L Stephens, P Goodman, E D Crawford, et al.
Cancer Immunology, Immunotherapy : CII
|
July 31, 2016
Beta-glucan contamination of pharmaceutical products: How much should we accept?
Claire Barton, Kim Vigor, Robert Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma
Sarah M Rudman, Michael B Jameson, Mark J McKeage, et al.
Biotechnology Progress
|
September 8, 2016
Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies
Kim Vigor, John Emerson, Robert Scott, et al.
Mabs
|
February 5, 2014
Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency
Louise Saul, Debra H Josephs, Keith Cutler, et al.
The Journal of Biological Chemistry
|
June 22, 2010
Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4
Scott Wilkie, Sophie E Burbridge, Laura Chiapero-Stanke, et al.
Antibodies (Basel, Switzerland)
|
October 21, 2020
IgE Antibodies against Cancer: Efficacy and Safety
Jitesh Chauhan, Alex J McCraw, Mano Nakamura, et al.
Molecular Cancer Therapeutics
|
November 12, 2014
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma
Kristina M Ilieva, Isabel Correa, Debra H Josephs, et al.
Page
of 8